We are dedicated to small-sized markets, which are less easy for major pharmaceutical companies to enter, such as cancer, hematology, and pain management. We will continue to increase revenue by aggressively launching innovative pharmaceuticals.
Our experts with extensive experience in drug discovery and evaluation drive our "New Drug Search Engine" to globally navigate through information about new drugs from bio-ventures, laboratories and pharmaceutical companies. They select, with their highly discerning capacity, the most promising and potentially most profitable drug candidates that are likely to meet compelling medical needs. Our Scientific Advisory Board, (SAB), comprised of experienced and professionally proven clinicians and scientists in basic research, provides impartial screening of the candidates and brings them into the pipelines.
We use clinical data previously obtained in other countries to allow our clinical studies to start at later development stages in order to complete the development process in an accelerated manner and acquire marketing approval at a higher rate. In addition, collaborating with other organizations enables a labless/fabless development scheme and low-cost management. This helps us maximize the value of your investment.
We acquired the rights to develop and commercialize this agent in 2005 and brought it to market in December 2010, only five years later. More than 11,000 patients with relapsed/refractory non-Hodgkin's lymphoma have received this anticancer agent.
Also, in August 2016, we obtained approval for chronic lymphocytic leukemia as an additional indication.
As well as these indications, in December 2016 SymBio obtained approval for the additional indication of first-line treatment of low-grade non-Hodgkin's lymphoma and mantle cell lymphoma, which will help even more patients and result in increased sales.
We acquired the exclusive license for this agent in 2011. We started a global phase 3 trial for IV rigosertib as a treatment for relapsed/refractory higher-risk myelodysplastic syndromes (MDS) in December 2015. We also started a phase 1 clinical trial for oral rigosertib in combination with azacitidine. Apart from this anticancer agent, there currently exists only one agent commercially available for MDS in Japan. The product has attracted strong interest from patients and the healthcare community.
We acquired an exclusive license for SyB P-1501 in October 2015. This combination agent for pain self-management is an innovative and patient-friendly system. It was already approved for commercialization in the U.S. and EU in 2015. We will soon start to prepare for a phase 3 clinical study in Japan.
SymBio Pharmaceuticals will continue to build on key products and aggressively add new pipelines.